Original research

ESR and CRP are useful between stages of 2-stage revision for periprosthetic joint infection

Christopher P. Lindsay, BS *, Christopher W. Olcott, MD, Daniel J. Del Gaizo, MD

Department of Orthopaedics, University of North Carolina School of Medicine, Chapel Hill, NC, USA

A R T I C L E  I N F O

Article history:
Received 16 June 2016
Accepted 11 August 2016
Available online 4 February 2017

Keywords:
Periprosthetic infection
2-stage revision
Erythrocyte sedimentation rate
C-reactive protein

A B S T R A C T

Background: Serum erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are important tests in the initial diagnosis of periprosthetic joint infection. Many surgeons also use these tests to determine if infection has resolved between stages of a 2-stage procedure, but little data exist regarding this practice.

Methods: A retrospective review of our institutional total joint databases was conducted to determine sensitivity, specificity, and predictive values of elevated ESR and/or CRP to diagnose persistent infection between stages.

Results: Among 16 knees and 5 hips, sensitivity was 50% for CRP, 75% for ESR, and 100% when combined. The negative predictive value of persistent infection was 100% when neither test was elevated.

Conclusions: Results of this study support the use of CRP and ESR as indicators of the resolution of periprosthetic joint infection between stages of 2-stage revision.

© 2016 Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Periprosthetic joint infection (PJI) is an important problem in hip and knee replacement surgery, as on average, between 1% and 2.5% [1,2] of patients undergoing primary total joint replacement of the hip or knee will suffer a deep PJI. Well-developed, evidence-based algorithms are in place for the initial diagnosis of PJI [3], and there is significant evidence to support the use of erythrocyte sedimentation rate (ESR) [1,2,4-8] and C-reactive protein (CRP) [2,4-6,8,9] as a part of these diagnostic criteria.

Following the initial PJI diagnosis, therapeutic options must be considered, including surgical revision and reimplantation (1 stage or 2 stage) or debridement with retention of some or all of the prosthetic components [10]. In North America, in the setting of chronic infection, 2-stage revision and reimplantation are most commonly performed [3]. In this procedure, the prosthetic components are removed, the joint is debrided, and an antibiotic eluting spacer is placed. A course of intravenous antibiotics is administered, and following resolution of infection, reimplantation with new components is usually undertaken. Unfortunately, there is no currently accepted algorithm to determine infection resolution between stages. Although well established as important tools to diagnose PJI, there is not yet reliable evidence that low ESR and/or CRP values can be used as an indicator of the elimination of infection or as a clinical marker for the timing of the second stage of surgical revision. The purpose of this study is to evaluate the usefulness of serum ESR and CRP levels in determining resolution of infection prior to reimplantation in 2-stage revision for treatment of PJI.

Material and methods

After institutional review board approval, a retrospective review of our institutional database was conducted to identify cases of PJI treated at our institution between July 1, 2004 and July 1, 2012. Following identification, patient records were accessed for evaluation for inclusion in the study. Inclusion criteria for this study were: patients with a history of plan for 2-stage revision and reimplantation following a diagnosis of periprosthetic infection of the hip or
knee joint according to the retrospectively applied Musculoskeletal Infection Society (MSIS) guidelines [11] with 2-year follow-up. Specifically, records were screened for infection with: communicating sinus tract with the prosthesis, or a pathogen isolated by culture from 2 or more fluid or tissue samples from the joint, or by fulfilling 4/6 of the following: (1) elevated ESR and CRP, (2) elevated synovial white blood cell count, (3) elevated synovial polymorphonuclear percentage, (4) presence of purulence in the affected joint, (5) culture isolation of a microorganism from one tissue or fluid sample, and (6) greater than 5 neutrophils per high power field in 5 fields at histologic examination at >400 magnification [11]. There were no exclusion criteria other than not meeting inclusion criteria. During the period described, 26 hips were identified that retrospectively met MSIS guidelines for infection. Of those patients, 19 were excluded because they were not primary total hip arthroplasty with a plan for 2-stage revision and 2 were excluded because they did not have an adequate follow-up period, leaving 5 hips included in the review. Over the same period, 55 knees were identified that met infection criteria, 39 were excluded because they were not primary total knee arthroplasty with plan for 2-stage revision, leaving 16 knees included. Overall, 21 consecutive 2-stage revisions for periprosthetic infection were identified that met inclusion criteria (16 knees, 5 hips).

In all cases, all components (and cement if present) were removed and an antibiotic-impregnated cement spacer was placed in the first stage of revision. All patients were treated with intravenous organism-specific antibiotics under consultation with infectious disease specialists. Patients were followed in clinic, and serial ESR and CRP measurements were obtained. The final decision regarding the second stage reimplantation occurred at the discretion of the treating surgeon when clinical, radiologic, and laboratory results were felt to be consistent with infection resolution.

For each patient that met inclusion criteria, relevant data were extracted from the medical record, including the ESR and CRP values before first-stage resection, as well as before the second stage reimplantation. An ESR greater than 30 mm/h and a CRP greater than 1 mg/dL were defined as elevated (positive) as suggested by the MSIS workgroup [11]. Persistent infection was defined as any clinical recurrence of PJI according to the aforementioned MSIS guidelines during a follow-up period of at least 2 years after reimplantation.

Results

In this series, reimplantation of the joint took place an average of 207 days after removal of prosthesis (range of 96-483 days). Following revision and reimplantation, 4 of the 21 reimplanted joints suffered from persistent periprosthetic infection. No significant differences in age of the patients or time interval between stages were noted between patients that cleared infection and patients that were classified as persistently infected (Table 1). While 3 out of the 4 (75%) patients who experienced persistent infection were female, there was no significant gender difference identified in patients in whom the infection was successfully eradicated. No significant difference in organisms isolated was identified in this study, and *Staphylococci* species were most commonly identified in this series (Table 2).

The mean ESR value before reimplantation was 15.4 (95% confidence interval [CI] 9.6-21.2) in patients without clinical recurrence and 39.0 (95% CI 27.0-51.0) in patients with persistent infection defined by clinical recurrence. In an unpaired, 2-tailed, Student *t* test, the *P* value of this difference was .0015. The mean CRP value before reimplantation was 0.75 (95% CI 0.10-1.40) in patients without clinical recurrence and 2.92 (95% CI 1.59-4.26) in patients with persistent infection defined by clinical recurrence. The *P* value of this difference was .0063.

Of the 17 patients who were successfully treated, 14 (67%) had normalization of both ESR and CRP before reimplantation. Alternatively, 3 patients (18%) had isolated CRP elevation, no patient had isolated ESR elevation, and no patient had both values elevated. Of the total 21 patients, 4 patients experienced recurrent periprosthetic infection, indicating a failure to eradicate infection before reimplantation. Of these 4 patients between stages before reimplantation, 1 had an isolated elevation of CRP, 2 had isolated ESR elevation, and 1 patient had elevation of both ESR and CRP. Test characteristics for ESR, CRP, and the 2 values combined were determined (Table 3). The sensitivity to detect persistent infection of ESR alone was 75%, with specificity of 100%, positive predictive value (PPV) of 100%, and negative predictive value (NPV) of 94.4%. For CRP alone, sensitivity was 50%, specificity was 82%, PPV 40%, and NPV 87.5%. ESR and CRP combined, performed better than the tests individually. Combined sensitivity, specificity, PPV, and NPV were all 100%. Patients who experienced persistent infection were seen to have either a markedly higher value for ESR, CRP, or both (Fig. 1). All patients that experienced successful eradication of infection can be seen to be either within or near the cutoff values for both ESR and CRP.

Discussion

The most notable result in our study is the NPV of ESR and CRP when used as a combined test. Of the 14 patients who experienced normalization of both markers before the second stage reimplantation of their prosthesis, none experienced clinical recurrence, yielding an NPV of 100%. This finding is consistent with expectations, as ESR and CRP are considered to be sensitive markers of inflammation. Ultimately, this study does support the hypothesis that if ESR and CRP are both within normal limits before reimplantation, infection has likely been eradicated.

An interesting observation was the high PPVs in our study, especially of ESR and of the 2 tests combined. We believe that this

| Category | Infection eradicated | Persistent infection |
|----------|----------------------|----------------------|
| Average age | 65.6 (95% CI 61.3-70.0) | 67.8 (95% CI 58.8-76.7) |
| Males | 10 (59%) | 1 (25%) |
| Females | 7 (41%) | 3 (75%) |
| Interval between stages | 202 d (95% CI 155-251) | 228 d (95% CI 129-327) |

The distribution of demographics of the patients included in analysis is shown. There were no significant differences in age, gender, or timing of second stage of revision seen in our study.

Table 2 Organisms identified in original PJI.

| Organism              | Infection eradicated | Persistent infection |
|-----------------------|----------------------|----------------------|
| MSSA                  | 3                    | 1                    |
| Ossa                  | 3                    | 2                    |
| Coag. neg. Staph.     | 2                    |                      |
| Diphtheroids          | 2                    |                      |
| Propionibacterium     | 1                    | 1                    |
| *E. coli*             | 1                    |                      |
| *Candida* spp.        | 1                    |                      |
| Culture negative      | 2                    |                      |
| No culture found      | 2                    |                      |

There was not a single predominant organism in either group. *Staphylococci* species were found in 3/4 patients with persistent infection; however *Staphylococci* species were also found in patients without persistent infection, and there is no significant difference in organisms isolated.
Persisting Infection demonstrated either dramatically elevated ESR, CRP, or both. Our search of the literature yielded 3 previous studies [12-14] literature studying ESR and CRP between stages of 2-stage revision. Despite their limitations, serum ESR and CRP continue to have utility as “rule-out” tests in the interim period between stages of a 2-stage revision. Though a clear cutoff remains difficult to identify, this study indicates that a clear difference exists in both ESR and CRP values between patients who clear infection and those in whom infection persists. Additionally, in patients in whom both serum values return to normal levels, the likelihood of persistent infection is low. More information in larger studies is needed to identify optimal cutoff values and timing of serum testing to improve how these tests inform clinical decisions, but based on the data in this study, these authors conclude that it is a reasonable practice at this time for surgeons to continue to follow ESR and CRP throughout revision and reimplantation for PJI. At our institution, we continue to obtain serum ESR and CRP values for patients between stages of 2-stage revision for PJI to help guide decision-making.

Acknowledgments

The authors thank the NIH, who partially supported this work under short-term research grant #T35DK007386-33, as well as the NC-Tracs Institute, who provided assistance with database searches and data review.

References

[1] Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003;36:1157.
[2] Schinsky MF, Della Valle CJ, Sporer SM, Paprosky WG. Perioperative testing for joint infection in patients undergoing revision total hip arthroplasty. J Bone Joint Surg Am 2008;90(9):1869.
[3] Parvizi J, Della Valle CJ. AAS Clinical Practice Guideline: diagnosis and treatment of periprosthetic joint infections of the hip and knee. J Am Acad Orthop Surg 2010;18:771.
[4] Bottner F, Wegner A, Winkelmann W, et al. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br 2007;89(1):94.
[5] Della Valle CJ, Sporer SM, Jacobs JF, et al. Preoperative testing for sepsis before revision total knee arthroplasty. J Arthroplasty 2007;22(6 Suppl 2):S90.
[6] Greidanus NV, Masri BA, Garbuz DS, et al. Use of erythrocyte sedimentation rate and C-reactive protein level to diagnose infection before revision total knee arthroplasty. A prospective evaluation. J Bone Joint Surg Am 2007;89(7):1405.
[7] Kamme C, Lindberg L. Aerobic and anaerobic bacteria in deep infections after total hip arthroplasty: differential diagnosis between infectious and non-infectious loosening. Clin Orthop Relat Res 1981;(154):201.
[8] Savarino L, Baldini N, Tarabusi C, Pellacani A, Giunti A. Diagnosis of infection after total hip replacement. J Biomed Mater Res B Appl Biomater 2004;70(1):139.
[9] Fink B, Makowiak C, Fuerst M, et al. The value of synovial biopsy, joint aspiration and C-reactive protein in the diagnosis of late peri-prosthetic infection of total knee replacements. J Bone Joint Surg Br 2008;90(7):874.
[10] Cuckler JM. The infected total knee: management options. J Arthroplasty 2007;20(4 suppl 2):33.
[11] Workgroup convened by the Musculoskeletal Infection Society. New definition for periprosthetic joint infection. J Arthroplasty 2011;26(6):1136.
[12] Shukla SK, Ward JP, Jacofsky MC, et al. Perioperative testing for persistent sepsis following resection arthroplasty of the hip for periprosthetic infection. J Arthroplasty 2010;25(6 suppl 1):87.
[13] Chanem E, Azzam K, Seeley M, Joshi A, Parvizi J. Staged revision for knee arthroplasty infection: What is the role of serologic tests before reimplantation? Clin Orthop Relat Res 2009;467:1699.
[14] Kusuma SK, Ward J, Jacofsky M, Sporer SM, Della Valle CJ. What is the role of serological testing between stages of two-stage reconstruction of the infected prosthetic knee? Clin Orthop Relat Res 2011;469:1002.